{"id":389925,"date":"2021-12-27T00:00:00","date_gmt":"2021-12-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0004-2021-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2021\/"},"modified":"2026-04-15T23:20:49","modified_gmt":"2026-04-15T23:20:49","slug":"dlsfim0004-2021-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0004-2021-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2021\/","title":{"rendered":"Crohn&#8217;s Disease | Disease Landscape and Forecast | G7 | 2021"},"content":{"rendered":"<p>The Crohn\u2019s disease (CD) therapy market is expected to see increasing use of biologics \/ targeted oral therapies and grow steadily over the next decade. The well-established TNF-\u03b1 inhibitors (e.g., infliximab, adalimumab [AbbVie \/ Eisai\u2019s Humira, biosimilars]), together with non-TNF biologics (i.e., Takeda\u2019s Entyvio and Janssen\u2019s Stelara), have transformed the treatment landscape for CD, especially for moderate to severe disease, despite these drugs\u2019 efficacy limitations and safety risks. The impending entry of several new therapies offering more-convenient formulations and\/or novel mechanisms of action (e.g., AbbVie\u2019s risankizumab and upadacitinib, Janssen\u2019s guselkumab, Galapagos \/ Gilead\u2019s filgotinib) will further improve treatment and intensify market competition. Together with these trends, the continuing generic erosion of conventional agents and the availability of biosimilar TNF-\u03b1 inhibitors and non-TNF-\u03b1 inhibitors will constrain CD therapy sales.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are KOLs\u2019 opinions of current targeted therapies (e.g., infliximab, adalimumab, Stelara, Entyvio)? How have biosimilars influenced treatment practices? What factors drive treatment decisions?<\/li>\n<li>What do KOLs think about emerging therapies (e.g., filgotinib, risankizumab, upadacitinib, guselkumab)? What impact will the stem cell therapy Alofisel (TiGenix \/ Takeda) and oral therapies have on the CD treatment algorithm?<\/li>\n<li>Which emerging agents are likely to be most successful in targeting TNF-refractory patients and gaining uptake in the CD market?<\/li>\n<li>How will the market evolve over the next 10 years?<\/li>\n<\/ul>\n<p><strong>CONTENT <\/strong><strong>HIGHLIGHTS<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan.<\/p>\n<p>Primary research: 34 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other DRG research.<\/p>\n<p>Epidemiology: Diagnosed prevalence of Crohn\u2019s disease by country, segmented by disease activity.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key Crohn\u2019s disease therapies through 2030, segmented by brands\/generics.<\/p>\n<p>Emerging therapies: Phase III\/PR: ~9 drugs; coverage of select Phase I and Phase II products.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>SOLUTION ENHANCEMENT<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-389925","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389925\/revisions"}],"predecessor-version":[{"id":576307,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389925\/revisions\/576307"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}